BACKGROUND: Black patients with neuroblastoma have a higher prevalence of high-risk disease and worse outcome than white patients. We sought to investigate the relationship between genetic variation and the disparities in survival observed in neuroblastoma. METHODS: The analytic cohort was composed of 2709 patients. Principal components were used to assign patients to genomic ethnic clusters for survival analyses. Locus-specific ancestry was calculated for use in association analysis. The shorter spans of linkage disequilibrium in African populations may facilitate the fine mapping of causal variants in regions previously implicated by genome-wide association studies conducted primarily in patients of European descent. Thus, we evaluated 13 single nucleotide polymorphisms known to be associated with susceptibility to high-risk neuroblastoma from genome-wide association studies and all variants with highly divergent allele frequencies in reference African and European populations near the known susceptibility loci. All statistical tests were two-sided. RESULTS: African genomic ancestry was associated with high-risk neuroblastoma (P = .007) and lower event-free survival (P = .04, hazard ratio = 1.4, 95% confidence interval = 1.05 to 1.80). rs1033069 within SPAG16 (sperm associated antigen 16) was determined to have higher risk allele frequency in the African reference population and statistically significant association with high-risk disease in patients of European and African ancestry (P = 6.42 × 10(-5), false discovery rate < 0.0015) in the overall cohort. Multivariable analysis using an additive model demonstrated that the SPAG16 single nucleotide polymorphism contributes to the observed ethnic disparities in high-risk disease and survival. CONCLUSIONS: Our study demonstrates that common genetic variation influences neuroblastoma phenotype and contributes to the ethnic disparities in survival observed and illustrates the value of trans-population mapping.
BACKGROUND: Black patients with neuroblastoma have a higher prevalence of high-risk disease and worse outcome than white patients. We sought to investigate the relationship between genetic variation and the disparities in survival observed in neuroblastoma. METHODS: The analytic cohort was composed of 2709 patients. Principal components were used to assign patients to genomic ethnic clusters for survival analyses. Locus-specific ancestry was calculated for use in association analysis. The shorter spans of linkage disequilibrium in African populations may facilitate the fine mapping of causal variants in regions previously implicated by genome-wide association studies conducted primarily in patients of European descent. Thus, we evaluated 13 single nucleotide polymorphisms known to be associated with susceptibility to high-risk neuroblastoma from genome-wide association studies and all variants with highly divergent allele frequencies in reference African and European populations near the known susceptibility loci. All statistical tests were two-sided. RESULTS: African genomic ancestry was associated with high-risk neuroblastoma (P = .007) and lower event-free survival (P = .04, hazard ratio = 1.4, 95% confidence interval = 1.05 to 1.80). rs1033069 within SPAG16 (sperm associated antigen 16) was determined to have higher risk allele frequency in the African reference population and statistically significant association with high-risk disease in patients of European and African ancestry (P = 6.42 × 10(-5), false discovery rate < 0.0015) in the overall cohort. Multivariable analysis using an additive model demonstrated that the SPAG16 single nucleotide polymorphism contributes to the observed ethnic disparities in high-risk disease and survival. CONCLUSIONS: Our study demonstrates that common genetic variation influences neuroblastoma phenotype and contributes to the ethnic disparities in survival observed and illustrates the value of trans-population mapping.
Authors: Howard M Cann; Claudia de Toma; Lucien Cazes; Marie-Fernande Legrand; Valerie Morel; Laurence Piouffre; Julia Bodmer; Walter F Bodmer; Batsheva Bonne-Tamir; Anne Cambon-Thomsen; Zhu Chen; J Chu; Carlo Carcassi; Licinio Contu; Ruofu Du; Laurent Excoffier; G B Ferrara; Jonathan S Friedlaender; Helena Groot; David Gurwitz; Trefor Jenkins; Rene J Herrera; Xiaoyi Huang; Judith Kidd; Kenneth K Kidd; Andre Langaney; Alice A Lin; S Qasim Mehdi; Peter Parham; Alberto Piazza; Maria Pia Pistillo; Yaping Qian; Qunfang Shu; Jiujin Xu; S Zhu; James L Weber; Henry T Greely; Marcus W Feldman; Gilles Thomas; Jean Dausset; L Luca Cavalli-Sforza Journal: Science Date: 2002-04-12 Impact factor: 47.728
Authors: Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich Journal: Nat Genet Date: 2006-07-23 Impact factor: 38.330
Authors: F Berthold; B Hero; H Breu; H Christiansen; R Erttmann; A Gnekow; F Herrmann; T Klingebiel; F Lampert; S Müller-Weihrich; P Weinel Journal: Ann Oncol Date: 1996-02 Impact factor: 32.976
Authors: John M Maris; Yael P Mosse; Jonathan P Bradfield; Cuiping Hou; Stefano Monni; Richard H Scott; Shahab Asgharzadeh; Edward F Attiyeh; Sharon J Diskin; Marci Laudenslager; Cynthia Winter; Kristina A Cole; Joseph T Glessner; Cecilia Kim; Edward C Frackelton; Tracy Casalunovo; Andrew W Eckert; Mario Capasso; Eric F Rappaport; Carmel McConville; Wendy B London; Robert C Seeger; Nazneen Rahman; Marcella Devoto; Struan F A Grant; Hongzhe Li; Hakon Hakonarson Journal: N Engl J Med Date: 2008-05-07 Impact factor: 91.245
Authors: Mark A Applebaum; Zalman Vaksman; Sang Mee Lee; Eric A Hungate; Tara O Henderson; Wendy B London; Navin Pinto; Samuel L Volchenboum; Julie R Park; Arlene Naranjo; Barbara Hero; Andrew D Pearson; Barbara E Stranger; Susan L Cohn; Sharon J Diskin Journal: Eur J Cancer Date: 2016-12-26 Impact factor: 9.162
Authors: Eric A Hungate; Mark A Applebaum; Andrew D Skol; Zalman Vaksman; Maura Diamond; Lee McDaniel; Samuel L Volchenboum; Barbara E Stranger; John M Maris; Sharon J Diskin; Kenan Onel; Susan L Cohn Journal: J Natl Cancer Inst Date: 2017-10-01 Impact factor: 13.506
Authors: Navin R Pinto; Mark A Applebaum; Samuel L Volchenboum; Katherine K Matthay; Wendy B London; Peter F Ambros; Akira Nakagawara; Frank Berthold; Gudrun Schleiermacher; Julie R Park; Dominique Valteau-Couanet; Andrew D J Pearson; Susan L Cohn Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Laura Fejerman; Donglei Hu; Scott Huntsman; Esther M John; Mariana C Stern; Christopher A Haiman; Eliseo J Pérez-Stable; Elad Ziv Journal: Cancer Res Date: 2013-10-31 Impact factor: 13.312
Authors: N Pinto; E R Gamazon; N Antao; J Myers; A L Stark; A Konkashbaev; H K Im; S J Diskin; W B London; S M Ludeman; J M Maris; N J Cox; S L Cohn; M E Dolan Journal: Clin Pharmacol Ther Date: 2014-02-18 Impact factor: 6.875
Authors: Skye Balyasny; Sang Mee Lee; Ami V Desai; Samuel L Volchenboum; Arlene Naranjo; Julie R Park; Wendy B London; Susan L Cohn; Mark A Applebaum Journal: JAMA Netw Open Date: 2021-07-01